Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;109(12):2699-2705.
doi: 10.1111/apa.15333. Epub 2020 May 20.

Follow-up of chronic paediatric hepatitis C virus in a low-/middle-income country

Mortada El-Shabrawi  1 , Sherif Baroudy  1 , Fetouh Hassanin  2 , Ahmed Saed Behairy  1 , Mostafa Yakoot  3 , Ayaat Ahmed  4
Affiliations

Follow-up of chronic paediatric hepatitis C virus in a low-/middle-income country

Mortada El-Shabrawi et al. Acta Paediatr. 2020 Dec.

Abstract

Aim: Follow-up of chronic hepatitis C virus (HCV) infection following Interferon (IFN) plus Ribavirin (RBV) or direct-acting antiviral (DAA) drug therapy in a cohort of paediatric outpatients as confirmed by a sustained virologic response (SVR).

Methods: This study included a cohort of 60 patients (6-18 years), divided into 2 groups: Group 1:21 patients who completed treatment with IFN/RBV. Group 2:39 treated with dual DAA therapy: 19 with Sofosbuvir/Ledipasvir (SOF/LED) and 20 with Sofosbuvir/Daclatasvir (SOF/DCV).

Results: Group 1:12 (57.1%) were cured, six were IFN/RBV treatment failure then subsequently treated with DAAs successfully, and three had liver transplants. IFN/RBV side effects were reported in all patients; however, fibrosis regressed in two cured patients. Group 2: all were cured. HCV RNA became negative in all DAAs-treated patients at weeks 2, 4 and 12 of treatment (100%) as well as SVR after 12 weeks (100%). Thirty patients reported no adverse side effects whereas only nine suffered minor side effects.

Conclusions: In our cohort, SOF/LED therapy and SOF/DCV therapy were extremely safe and effective with 100% SVR and negligible short-term side effects. IFN/RBV therapy was much less effective (SVR 57.1%) and accompanied with short-term side effects. Fibrosis might stop and even regress with successful treatment.

Keywords: DAAs; HCV; SVR; interferon; paediatrics.

PubMed Disclaimer

References

REFERENCES

    1. El-Shabrawi MH, Kamal NM. Burden of pediatric hepatitis C. WORLD J GASTROENTERO. 2013;19(44):7880.
    1. Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC infect dis. 2013;13(1):288.
    1. Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastro Hepat. 2017;14(2):122.
    1. World Health Organization (WHO). Global hepatitis report. http://www.who.int/news-room/detail/27-07-2017-eliminate-hepatitis-who. Organization WH. Geneva. 2017. Accessed February 11, 2020.
    1. Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenerol. 2016;22(34):7824.

Substances

LinkOut - more resources